The FDA's Breakthrough Therapy Designation is a significant positive development for Ensysce Biosciences, indicating that PF614-MPAR has the potential to address a serious condition more effectively than existing therapies. This designation can lead to expedited development and review processes, which may enhance investor optimism about the drug's prospects and the company's future performance. As a result, the stock price is likely to experience upward pressure in the short term.